Loading
MINDACT showed that women whose early breast cancer looked high-risk to doctors but low-risk on the 70-gene MammaPrint test could skip chemotherapy: those who did met the trial's prespecified safety threshold, and about 46% of clinically high-risk women could avoid chemotherapy. Women aged 50 or under may still gain from it.
Among 6,693 women, 1,550 had high clinical risk but low genomic risk by MammaPrint; those randomised to no chemotherapy had 5-year distant metastasis-free survival of 94.7% (NEJM 2016), meeting the prespecified threshold, with a 1.5 percentage point difference versus chemotherapy that was not statistically significant. The 8-year update (Lancet Oncology 2021) confirmed the finding, with a suggestion of chemotherapy benefit in women aged 50 or under. About 46% of clinically high-risk women could avoid chemotherapy.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
6,693 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| 5-year distant metastasis-free survival, clinical-high / genomic-low risk, no chemotherapyprimary | No chemotherapy (genomic risk) | - | 94.7% | - | - | link |
One trial page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
One trial page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
This is the paper Europe PMC returns for registry id NCT00433589 with the most citations, so it is the natural first reading for anyone following the MINDACT trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
Shares MammaPrint (70-gene signature), Enrichment and biomarker-stratified designs, High-risk early HR-positive breast cancer, RNA sequencing & expression profiling.
Shares MammaPrint (70-gene signature), RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
Shares MammaPrint (70-gene signature), Enrichment and biomarker-stratified designs, High-risk early HR-positive breast cancer, RNA sequencing & expression profiling.
Shares Pre-specified vs post-hoc analysis, Enrichment and biomarker-stratified designs.
Shares MammaPrint (70-gene signature), RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
Shares Enrichment and biomarker-stratified designs, High-risk early HR-positive breast cancer, RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.
Shares MammaPrint (70-gene signature), HR-positive / HER2-negative breast cancer.
Shares Breast International Group (BIG), EORTC, RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer.